Trans-pulmonary Biomarkers in Pulmonary Hypertension



Status:Active, not recruiting
Conditions:High Blood Pressure (Hypertension), High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:1/13/2019
Start Date:August 2013
End Date:December 2020

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy

The investigators are testing whether the addition of Pulmonary Hypertension-related
biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation
for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension
therapy and improved patient outcomes.

Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically
indicated right heart catheterization may be enrolled. Clinical data and blood samples will
be analyzed.

Inclusion Criteria:

- Age ≥ 18 years old

- Undergoing RHC for PH evaluation

Exclusion Criteria:

- Anemia defined as Hgb < 10 g/dL and HCT < 30

- Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day
of the procedure)

- Left ventricular ejection fraction ≤ 40%

- Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on
the day of the procedure)

- IPF, CTEPH, COPD/OSA as the dominant etiology of PH

- Patient is currently taking PH medication or long-acting nitrates at the time of their
RHC.
We found this trial at
1
site
Vanderbilt University Medical Center
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials